… We therefore conducted a phase II trial to assess the safety and efficacy of single agent
cetuximab in patients with chemotherapy-refractory metastatic colorectal cancers that express …

… As in any phase II trial, our results apply only to the dose and … -2–positive breast cancer.
Results of this study have led to a multicenter phase II trial of lapatinib in patients with HER-2–…

… We report the first phase II study of ZD6474, an inhibitor of the VEGFR-2 and EGFR
tyrosine kinases, in patients with metastatic breast cancer. All patients had received prior …

… in a number of phase II studies, with response … phase II trials of trastuzumab plus docetaxel
provided a strong rationale for investigating trastuzumab and docetaxel in a randomized trial. …

… in exons 18–21 of the epidermal growth factor receptor (EGFR) gene are a predictor of
response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib …

… the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among …
Stage IIIB/IV NSCLC, chemotherapy-naive patients or patients with recurrences after up to two …

… In conclusion, this randomized phase II trial suggests that tamoxifen combined with …
Taken together with the results of the BOLERO-2 trial (pending survival results), these data …

… phase 2 study, we enrolled patients from 30 centres in Taiwan and the USA with lung
adenocarcinoma (stage IIIb with pleural effusion or stage … status of 0–2, and no previous treatment …

… Pertuzumab, a human epidermal growth factor receptor 2 (HER2) –targeted monoclonal …
This phase II trial assessed the efficacy and safety profile of the combination in patients with …

… growth factor receptor 2 (HER2)-positive breast cancer 10,11 and cKIT-positive GI stromal
tumors. Several clinical trials … /CTONG1104 trial, 13-17 which was a randomized phase III trial …